ISRCTN58401737进行中（未招募）未知
Additional Treatments to the Local tumour for metastatic prostate cancer: Assessment of Novel Treatment Algorithms
Imperial College London and Imperial College Healthcare NHS Trust0 个研究点目标入组 399 人开始时间: 2018年11月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 399
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Diagnosed with prostate cancer within 6 months of screening visit
- •2. Metastatic disease (Any T, Any N, M1+) of any grade, stage or Prostate Specific Antigen (PSA) level
- •3. Fit to undergo standard of care treatment for metastatic disease and both minimally invasive therapy and prostate radiotherapy/prostatectomy
- •4. Performance status 0-2
- •5. Histologically proven local tumour
排除标准
- •Added 23/08/2023: Current exclusion criteria as of 06/10/2021:
- •1. Patient did not undergo and/or is unable to undergo standard of care baseline imaging tests for confirmation of metastatic status (CT abdomen/pelvis AND chest X-ray (or CT chest) AND radioisotope bone scan (or whole body imaging such as MRI or PET imaging as alternative to all preceding scans mentioned here) AND prostate MRI.
- •2. Prior exposure to long-term androgen deprivation therapy or hormonal therapy for the treatment of prostate cancer unless started within 6 months of screening visit.
- •3. Prior chemotherapy or local or systemic therapy for treatment of prostate cancer (apart from ADT or hormonal therapy as outlined above)
- •Previous exclusion criteria from 08/02/2021 to 06/10/2021:
- •1. Patient did not undergo and/or is unable to undergo standard of care baseline imaging tests for confirmation of metastatic status (CT abdomen/pelvis AND chest X-Ray (or CT chest) AND radioisotope bone scan (or whole body imaging such as MRI or PET imaging as alternative to all
- •preceding scans mentioned here) AND prostate MRI
- •2. Prior exposure to long-term androgen deprivation therapy or hormonal therapy for the treatment of prostate cancer unless started within 4 months of screening visit
- •3. Prior chemotherapy or local or systemic therapy for treatment of prostate cancer (apart from ADT or hormonal therapy as outlined above in Exclusion Criteria 2)
- •Previous exclusion criteria:
- •1. Patient did not undergo and/or is unable to undergo standard of care baseline imaging tests for confirmation of metastatic status (CT abdomen/pelvis AND chest X-Ray (or CT chest) AND radioisotope bone scan (or whole body imaging such as MRI or PET imaging as alternative to all preceding scans mentioned here) AND prostate MRI
- •2. Prior exposure to long-term androgen deprivation therapy or hormonal therapy for the treatment of prostate cancer unless started within 3 months of randomisation
- •3. Prior chemotherapy or local or systemic therapy for treatment of prostate cancer (apart from ADT or hormonal therapy as outlined above in Exclusion Criteria 2)
研究者
相似试验
进行中（未招募）
不适用
Treatment of locally advanced or metastatic non-small cell lung cancer with Pemetrexed (Alimta) and Gemcitabine or Gemcitabine and Carboplatin: The PAGe study. - The PAGe studyEUCTR2005-001577-97-SEGunnar Hillerdal96
尚未招募
2 期
Treatment of limited Oligo Metastatic disease in Esophageal and Stomach carcinoma; TOMES trialstomach and esophagus cancerupperGi cancer10017990NL-OMON52125Antoni van Leeuwenhoek Ziekenhuis73
进行中（未招募）
1 期
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastasen.EUCTR2022-000066-18-BEniversitaire Ziekenhuizen Leuven873
招募中
1 期
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastases.Oligorecurrent hormone-sensitive prostate cancer patientsCTIS2022-502373-42-00Z Leuven873
进行中（未招募）
不适用
[Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus]Target-specific therapy of metastatic urothelial carcinoma with temsirolimus - Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit TemsirolimusChemotherapy refractory metastatic urothelia carcinomaMedDRA version: 9.1Level: LLTClassification code 10064467Term: Urothelial carcinomaEUCTR2008-008478-30-DEukaskrankenhaus GmbH